Brivaracetam in the Treatment of Patients with Epilepsy-First Clinical Experiences

Frontiers in Neurology
Felix ZahnertSusanne Knake

Abstract

To assess first clinical experiences with brivaracetam (BRV) in the treatment of epilepsies. Data on patients treated with BRV from February to December 2016 and with at least one clinical follow-up were collected from electronic patient records. Data on safety and efficacy were evaluated retrospectively. In total, 93 patients were analyzed; 12 (12.9%) received BRV in monotherapy. The mean duration to follow-up was 4.85 months (MD = 4 months; SD = 3.63). Fifty-seven patients had more than one seizure per month at baseline and had a follow-up of more than 4 weeks; the rate of ≥50% responders was 35.1% (n = 20) in this group, of which five (8.8%) patients were newly seizure-free. In 50.5% (47/93), patients were switched from levetiracetam (LEV) to BRV, of which 43 (46.2%) were switched immediately. Adverse events (AE) occurred in 39.8%, with 22.6% experiencing behavioral and 25.8% experiencing non-behavioral AE. LEV-related AE (LEV-AE) were significantly reduced by switching to BRV. The discontinuation of BRV was reported in 26/93 patients (28%); 10 of those were switched back to LEV with an observed reduction of AE in 70%. For clinical reasons, 12 patients received BRV in monotherapy, 75% were seizure-free, and previous LEV-AE i...Continue Reading

References

Feb 5, 2000·The New England Journal of Medicine·P Kwan, M J Brodie
Jun 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Berkley A LynchBruno Fuks
Feb 3, 2007·Seizure : the Journal of the British Epilepsy Association·Steve ChungNicole Hank
Oct 29, 2015·Acta Neurologica Scandinavica·E TrinkaM J Brodie
Feb 20, 2016·Expert Review of Clinical Pharmacology·Adam StrzelczykSebastian Bauer
Apr 12, 2016·Seizure : the Journal of the British Epilepsy Association·Aleksei RakitinSulev Haldre
May 30, 2016·Seizure : the Journal of the British Epilepsy Association·Lin ZhangXiaoyi Zou
Jul 9, 2016·Der Nervenarzt·A StrzelczykS Bauer
Apr 2, 2017·Seizure : the Journal of the British Epilepsy Association·Bernhard J SteinhoffAnke M Staack

❮ Previous
Next ❯

Citations

Dec 7, 2018·Acta Neurologica Scandinavica·Vicente VillanuevaUNKNOWN BRIVA-LIFE study group
Nov 7, 2019·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Jeanne LafortuneJean-François Clément
Mar 12, 2020·Acta neurologica Belgica·Ruby M E GillisMarian H J M Majoie
Sep 17, 2019·Therapeutic Advances in Neurological Disorders·Bernhard J Steinhoff, Anke M Staack
Apr 30, 2019·JAAPA : Official Journal of the American Academy of Physician Assistants·Van HellersliaAbiemwense Iyamu
Feb 1, 2021·Epilepsy & Behavior : E&B·Linda Stephen, Martin J Brodie
Apr 28, 2021·Neurology India·Madhuri KhilariBrajesh Kumar Jha
Aug 18, 2018·Seizure : the Journal of the British Epilepsy Association·Martin HirschAndreas Schulze-Bonhage

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Seizure : the Journal of the British Epilepsy Association
Bernhard J SteinhoffAnke M Staack
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Zhi-Jie Gao, Yu-Wu Jiang
Epileptic Disorders : International Epilepsy Journal with Videotape
Shigeya Tanaka, Tatsuya Tanaka
Seizure : the Journal of the British Epilepsy Association
Salvatore GrossoPaolo Balestri
Neurología : publicación oficial de la Sociedad Española de Neurología
M AlegreC Viteri
© 2022 Meta ULC. All rights reserved